keyword
MENU ▼
Read by QxMD icon Read
search

liver trials cancer

keyword
https://www.readbyqxmd.com/read/29220110/non-responsiveness-and-susceptibility-of-opioids-side-effects-related-to-cancer-patients-clinical-characteristics-a-post-hoc-analysis
#1
Oscar Corli, Anna Roberto, Michael I Bennett, Francesca Galli, Nicole Corsi, Eliana Rulli, Raffaella Antonione
BACKGROUND: Response to opioids is not always positive in cancer patients. A considerable proportion of patients do not respond (non-responders, NRs) or experience severe toxicity. The aim of this analysis was to assess the role of demographic characteristics, pain features, comorbidities and ongoing therapy on the lack of efficacy and on the occurrence of severe adverse drug reactions (ADRs). METHODS: This is a post-hoc analysis of a randomized controlled trial that involved 520 patients and was aimed to evaluate the efficacy and safety of four strong opioids...
December 8, 2017: Pain Practice: the Official Journal of World Institute of Pain
https://www.readbyqxmd.com/read/29219177/current-status-and-future-prospective-of-curcumin-as-a-potential-therapeutic-agent-in-the-treatment-of-colorectal-cancer
#2
REVIEW
Mohammad Jalili-Nik, Arash Soltani, Soussan Moussavi, Majid Ghayour-Mobarhan, Gordon A Ferns, Seyed Mahdi Hassanian, Amir Avan
Colorectal cancer (CRC) is the third most common cause of cancer-related deaths worldwide. Hence there is a need to identify new therapeutic agents that improve the current repertoire of chemotherapeutic drugs. The antitumor activity of curcumin has been reported for several tumors, including CRC. A recent phase I trial showed that curcumin is safe and tolerable adjunct to FOLFOX (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in patient-derived colorectal liver metastases at doses up to 2 grams daily...
December 8, 2017: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29214884/adjuvant-intraperitoneal-chemotherapy-for-the-treatment-of-colorectal-cancer-at-risk-for-peritoneal-carcinomatosis-a-systematic-review
#3
Paul L Feingold, Nicholas D Klemen, Mei Li M Kwong, Barry Hashimoto, Udo Rudloff
BACKGROUND: The peritoneal surface is the second most common site of disease recurrence, after the liver, following definitive surgery for colorectal cancer. Adjuvant intraperitoneal (IP) chemotherapy delivered at time of surgical resection has the potential to delay or prevent future spread to the peritoneal surface and improve clinical outcome. The exact role of adjuvant IP chemotherapy in colorectal cancer, including its associated morbidity and mortality, is not well defined. STUDY DESIGN: Systematic review and pooled random effect analysis of comparative trials examining the addition of adjuvant IP chemotherapy compared to surgery alone in colorectal cancer...
December 7, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/29212194/association-between-mir-31-3p-expression-and-cetuximab-efficacy-in-patients-with-kras-wild-type-metastatic-colorectal-cancer-a-post-hoc-analysis-of-the-new-epoc-trial
#4
Siân Pugh, Raphaële Thiébaut, John Bridgewater, Marie-Lise Grisoni, Karwan Moutasim, Francis Rousseau, Gareth J Thomas, Gareth Griffiths, François Liebaert, John Primrose, Pierre Laurent-Puig
Background: High miR-31-3p expression is associated with inferior outcomes in KRAS wild-type (WT) advanced colorectal cancer patients treated with anti-EGFR therapy. This study evaluated miR-31-3p expression in patients with operable colorectal liver metastases (LM) enrolled in the New EPOC study. Methods: MiR-31-3p expression was measured in primary tumors (PT) from 149 KRAS WT patients including 71 receiving chemotherapy alone (CT) and 78 receiving chemotherapy plus cetuximab (CTX)...
November 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/29199678/ceritinib-in-anaplastic-lymphoma-kinase-positive-nonsmall-cell-lung-cancer-among-patients-who-were-previously-exposed-to-crizotinib-experience-from-the-indian-subcontinent
#5
A P Joshi, M V Chandrakanth, V Noronha, V Patil, A Chougule, A Mahajan, A K Janu, R Chanana, K Prabhash
Ceritinib is a novel ALK inhibitor approved for advanced stage NSCLC with ALK gene rearrangement, progressed and/or intolerant to crizotinib. 13 patients were included in our study who received ceritinib. Majority of them were women and never smokers with a median age of 47 yrs. Nearly half of them had a compromised performance status and received ceritinib in third line and beyond. Ceritinib showed nearly 50% response rates. With a median follow up of 9 months for the entire cohort, median PFS and OS were not reached...
January 2017: Indian Journal of Cancer
https://www.readbyqxmd.com/read/29199380/liver-resection-for-hcc-outside-the-bclc-criteria
#6
Manish S Bhandare, Shraddha Patkar, Nitin Shetty, Ashwin Polnaya, Suyash Kulkarni, Rohit R Dusane, Shailesh V Shrikhande, Mahesh Goel
PURPOSE: Surgical resection still remains the mainstay of management of hepatocellular carcinoma (HCC). At present, Barcelona clinic liver cancer (BCLC) staging is the most widely used tool to guide treatment; however, criteria for offering surgery as curative treatment are restrictive. We aimed to evaluate short-term and long-term outcomes of HCC after resection, even for patients outside BCLC criteria for resection. METHODS: Data was collected from a prospective database from GI and HPB Department, Tata Memorial Hospital, Mumbai...
December 4, 2017: Langenbeck's Archives of Surgery
https://www.readbyqxmd.com/read/29198327/critical-features-and-challenges-associated-with-imaging-in-patients-undergoing-cancer-immunotherapy
#7
REVIEW
Cinzia Solinas, Michele Porcu, Zuzana Hlavata, Pushpamali De Silva, Marco Puzzoni, Karen Willard-Gallo, Mario Scartozzi, Luca Saba
Manipulating an individual's immune system through immune checkpoint blockade is revolutionizing the paradigms of cancer treatment. Peculiar patterns and kinetics of response have been observed with these new drugs, rendering the assessment of tumor burden particularly challenging in cancer immunotherapy. The mechanisms of action for immune checkpoint blockade, based upon engagement of the adaptive immune system, can generate unusual response patterns, including pseudoprogression, hyperprogression, atypical and delayed responses...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29194365/the-role-of-resveratrol-in-cancer-therapy
#8
REVIEW
Jeong-Hyeon Ko, Gautam Sethi, Jae-Young Um, Muthu K Shanmugam, Frank Arfuso, Alan Prem Kumar, Anupam Bishayee, Kwang Seok Ahn
Abstract: Natural product compounds have recently attracted significant attention from the scientific community for their potent effects against inflammation-driven diseases, including cancer. A significant amount of research, including preclinical, clinical, and epidemiological studies, has indicated that dietary consumption of polyphenols, found at high levels in cereals, pulses, vegetables, and fruits, may prevent the evolution of an array of diseases, including cancer. Cancer development is a carefully orchestrated progression where normal cells acquires mutations in their genetic makeup, which cause the cells to continuously grow, colonize, and metastasize to other organs such as the liver, lungs, colon, and brain...
December 1, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29191606/response-rates-to-single-agent-chemotherapy-after-exposure-to-immune-checkpoint-inhibitors-in-advanced-non-small-cell-lung-cancer
#9
Gustavo Schvartsman, S Andrew Peng, Giorgios Bis, J Jack Lee, Marcelo F K Benveniste, Jianjun Zhang, Emily B Roarty, Lara Lacerda, Stephen Swisher, John V Heymach, Frank V Fossella, William N William
INTRODUCTION: Exploratory analysis of clinical trials in various tumor types have demonstrated potential improvements in overall response rate (ORR) to chemotherapy after exposure to vaccine-based immunotherapy. The objective of this retrospective study was to determine if single-agent chemotherapy (3rd-line or beyond) would yield improved ORR when given after exposure to programmed death-(ligand)1 inhibitors (anti-PD1) in metastatic non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We queried the Thoracic GEMINI database of MD Anderson Cancer Center for patients treated between 06/12 and 11/16 who received at least one single-agent chemotherapy as 3rd-line or beyond, following progression after platinum-based chemotherapy and anti-PD1...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29190996/surgical-resection-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus-in-the-asia-pacific-region-beyond-the-barcelona-clinic-liver-cancer-treatment-algorithms-a-review-and-update
#10
REVIEW
Jia-Zhou Ye, Yan-Yan Wang, Tao Bai, Jie Chen, Bang-De Xiang, Fei-Xiang Wu, Le-Qun Li
Portal vein tumor thrombus (PVTT) usually worsens prognosis of hepatocellular carcinoma (HCC), as characterized by aggressive disease progression, impaired liver function and tolerance to treatment. Conventionally, the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD) accepted the Barcelona Clinical Liver Cancer (BCLC) treatment algorithms, identifying PVTT as an absolute contra-indication of surgical resection for HCC. HCC-PVTT patients are offered sorafenib as the standard treatment...
November 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29188773/sorafenib-tosylate-ribavirn-and-sofosbuvir-combination-therapy-for-hcv-virus-infected-patients-with-decompensated-liver-cancer
#11
Bushra Munir, Bilal Ahmed, Shumaila Kiran, Fatima Jalal, Muhammad Kashif Zahoor, Saba Shehzadi, Sadaf Oranab, Sayed Kashif Kamran, Abdul Ghaffar
Hepatitis C is the most common health problem worldwide and is major cause of death due to proliferation of hepatocellular carcinoma. The medicines available for HCV treatment overcome up-to 95% complications of HCV. However, liver cancer needs some additional care. Normally Sorafenib tosylate 200 mg is recommended for liver cancer. There is no such trial in which this drug could effectively be used in combination of direct acting antivirals for HCV. The study was conducted for HCV patients (n=30) with liver cancer having decompensated stage...
November 2017: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29183960/radium-223-safety-efficacy-and-concurrent-use-with-abiraterone-or-enzalutamide-first-u-s-experience-from-an-expanded-access-program
#12
Oliver Sartor, Nicholas J Vogelzang, Christopher Sweeney, Daniel C Fernandez, Fabio Almeida, Andrei Iagaru, Alan Brown, Matthew R Smith, Manish Agrawal, Adam P Dicker, Jorge A Garcia, Jose Lutzky, Yu-Ning Wong, Oana Petrenciuc, Jeremy Gratt, Neal D Shore, Michael J Morris
BACKGROUND: In the phase III ALSYMPCA trial, metastatic castration-resistant prostate cancer (mCRPC) patients had few prior life-prolonging therapies. Following ALSYMPCA, which demonstrated radium-223 survival benefit, and before radium-223 U.S. commercial availability, an expanded access program (EAP) providing early-access radium-223 allowed life-prolonging therapies in current use. SUBJECTS, MATERIALS, AND METHODS: This phase II, open-label, single-arm, multicenter U...
November 28, 2017: Oncologist
https://www.readbyqxmd.com/read/29177608/identification-of-educational-gaps-among-oncologists-who-manage-patients-with-pancreatic-cancer
#13
Justin A Barnes, Melissa L Ellis, Sharon Hwang, Joan Emarine, Patti Merwin, Gregory D Salinas, Benjamin L Musher
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDA) is associated with poor outcomes and presents oncologists with a myriad of clinical challenges. This study was conducted to assess oncologists' practice patterns and to identify the greatest areas of need for future PDA continuing medical education (CME) programs. METHODS: Case vignettes have been validated as an effective tool to assess how physicians approach and treat a wide array of diseases. In order to assess practice patterns for resectable, locally advanced unresectable, and metastatic PDA, an online case vignette survey was distributed to practicing medical oncologists...
November 27, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/29168107/predictive-factors-of-trastuzumab-based-chemotherapy-in-her2-positive-advanced-gastric-cancer-a-single-center-prospective-observational-study
#14
Q Li, H Li, H Jiang, Y Feng, Y Cui, Y Wang, Y Ji, Y Yu, W Li, C Xu, S Yu, R Zhuang, T Liu
PURPOSE: Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the clinicopathologic factors that predict the outcome of routine trastuzumab therapy remain unclear. METHODS: The outcome and safety profile of trastuzumab therapy in untreated HER2 positive AGC was evaluated in this prospective observational study. Clinical and pathological data including demographics, treatment profiles, expression level of HER2 were analyzed to identify predictive factors of trastuzumab-based first-line therapy for their progression-free survival (PFS)...
November 22, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29167102/coffee-consumption-and-health-umbrella-review-of-meta-analyses-of-multiple-health-outcomes
#15
Robin Poole, Oliver J Kennedy, Paul Roderick, Jonathan A Fallowfield, Peter C Hayes, Julie Parkes
Objectives To evaluate the existing evidence for associations between coffee consumption and multiple health outcomes.Design Umbrella review of the evidence across meta-analyses of observational and interventional studies of coffee consumption and any health outcome.Data sources PubMed, Embase, CINAHL, Cochrane Database of Systematic Reviews, and screening of references.Eligibility criteria for selecting studies Meta-analyses of both observational and interventional studies that examined the associations between coffee consumption and any health outcome in any adult population in all countries and all settings...
November 22, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29165684/can-biomarkers-advance-hiv-research-and-care-in-the-art-era
#16
Amy C Justice, Kristine M Erlandson, Paolo G Miotti, Alan Landay, Peter W Hunt, Russell P Tracy
Despite achieving HIV-1 RNA suppression below levels of detection and, for most, improved CD4 counts, those aging with HIV experience excess low-level inflammation, hypercoagulability, and immune dysfunction (chronic inflammation) compared to demographically and behaviorally similar uninfected individuals. A host of biomarkers that are linked to chronic inflammation are also associated with HIV-associated non-AIDS events including cardiovascular disease, many forms of cancer, liver disease, renal disease, neurocognitive decline, and osteoporosis...
November 20, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29158365/phase-ii-trial-using-a-combination-of-oxaliplatin-capecitabine-and-celecoxib-with-concurrent-radiation-for-newly-diagnosed-resectable-rectal-cancer
#17
Emilio P Araujo-Mino, Yehuda Z Patt, Cristina Murray-Krezan, Joshua A Hanson, Pranshu Bansal, Ben J Liem, Ashwani Rajput, M Houman Fekrazad, Glenory Heywood, Fa Chyi Lee
LESSONS LEARNED: Colorectal cancers exhibit a high level of cyclooxygenase-2 (COX-2) expression with strong preclinical rationale for improved clinical outcomes with COX-2 inhibition. Celecoxib is a COX-2 inhibitor and we have shown that it can be safely combined with capecitabine and oxaliplatin as part of neoadjuvant treatment with radiation therapy (RT) in rectal cancer.There was a significant improvement in skin toxicity with this combination as compared with historical data. Considering the field has moved on to single-agent capecitabine, we believe future trials with capecitabine and celecoxib hold potential...
November 20, 2017: Oncologist
https://www.readbyqxmd.com/read/29157287/safety-in-treatment-of-hepatocellular-carcinoma-with-immune-checkpoint-inhibitors-as-compared-to-melanoma-and-non-small-cell-lung-cancer
#18
Zachary J Brown, Bernd Heinrich, Seth M Steinberg, Su Jong Yu, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is a major health problem worldwide with increasing incidence rates. As HCC traditionally occurs in chronically inflamed livers, this inflammation aids to drive oncogenesis and often renders these lesions to be immunogenic and therefore potential targets for immunotherapy. As patients with HCC generally have underlying liver dysfunction, we sought to determine if immune checkpoint inhibitors were safe to use in patients with HCC as compared to melanoma and non-small cell lung cancer (NSCLC) in terms of the gastrointestinal side effects of elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and diarrhea as well as patients who drop out of the study due to drug toxicity and death secondary to drug toxicity...
November 21, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29150395/transradial-versus-transfemoral-arterial-access-in-liver-cancer-embolization-randomized-trial-to-assess-patient-satisfaction
#19
Ricardo Yamada, Stephen Bracewell, Beatriz Bassaco, Juan Camacho, M Bret Anderson, Andrew Conrad, Corie Lynn, Paul Burns, Heather Collins, Marcelo Guimaraes
PURPOSE: To determine whether transradial access (TRA) or transfemoral access (TFA) provides better patient satisfaction during intra-arterial therapy (IAT) for liver cancer. MATERIALS AND METHODS: This randomized, prospective, intra- and interpatient controlled trial compared TRA vs TFA accesses in patients with primary or metastatic liver cancer undergoing IAT. After having one of each type of access (1 TRA and 1 TFA), all patients selected their preferred access regardless of whether a third intervention was indicated...
November 15, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29146695/first-in-human-her2-targeted-imaging-using-89-zr-pertuzumab-pet-ct-dosimetry-and-clinical-application-in-patients-with-breast-cancer
#20
Gary A Ulaner, Serge K Lyashchenko, Christopher Riedl, Shutian Ruan, Pat B Zanzonico, Diana Lake, Komal Jhaveri, Brian Zeglis, Jason S Lewis, Joseph A O'Donoghue
In this first-in-human study, we evaluate the safety and dosimetry of (89)Zr-pertuzumab PET/CT for HER2-targeted imaging in patients with HER2-postive breast cancer. Materials and Methods: Patients with HER2-positive breast cancer and evidence of distant metastases were enrolled in an Institutional Review Board (IRB)-approved prospective clinical trial. Pertuzumab was conjugated with deferoxamine and radiolabeled with (89)Zr. Patients underwent (89)Zr-pertuzumab PET/CT with 74 MBq of (89)Zr-pertuzumab in a total antibody mass of 20-50 mg of pertuzumab...
November 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
28809
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"